Review Article

Investigating Polyphenol Nanoformulations for Therapeutic Targets against Diabetes Mellitus

Fahadul Islam, Jannatul Fardous Khadija, Md. Rezaul Islam, Sheikh Shohag, Saikat Mitra, Saad Alghamdi, Ahmad O. Babalghith, Abdulrahman Theyab, Mohammad Tauhidur Rahman, Aklima Akter, Abdullah Al Mamun, Fahad A. Alhumaydhi, and Talha Bin Emran

1 Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh
2 Department of Biochemistry and Molecular Biology, Faculty of Life Science, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh
3 Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh
4 Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia
5 Medical Genetics Department, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
6 Deputy Manager of Laboratory & Blood Bank, Security Forces Hospital, Makkah, Saudi Arabia
7 Department of Cardiology, Z. U Model Hospital, Feni 3900, Bangladesh
8 Molecular Pharmacology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China
9 Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 52571, Saudi Arabia
10 Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh

Correspondence should be addressed to Talha Bin Emran; talhabmb@gmail.com

Received 1 April 2022; Accepted 3 June 2022; Published 21 June 2022

Academic Editor: Xuanqin Chen

Copyright © 2022 Fahadul Islam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Diabetes mellitus (DM) is a fatal metabolic disorder, and its prevalence has escalated in recent decades to a greater extent. Since the incidence and severity of the disease are constantly increasing, plenty of therapeutic approaches are being considered as a promising solution. Many dietary polyphenols have been reported to be effective against diabetes along with its accompanying vascular consequences by targeting multiple therapeutic targets. Additionally, the biocompatibility of these polyphenols raises questions about their use as pharmacological mediators. Nevertheless, the pharmacokinetic and biopharmaceutical properties of these polyphenols limit their clinical benefit as therapeutics. Pharmaceutical industries have attempted to improve compliance and therapeutic effects. However, nanotechnological approaches to overcome the pharmacokinetic and biopharmaceutical barriers associated with polyphenols as antidiabetic medications have been shown to be effective to improve clinical compliance and efficacy. Therefore, this review highlighted a comprehensive and up-to-date assessment of polyphenol nanoformulations in the treatment of diabetes and vascular consequences.

1. Introduction

Diabetes mellitus (DM), also known as diabetes, is a metabolic group of disorders and can be characterized by chronic hyperglycemia (high blood sugar levels) [1]. The most prevalent symptoms include increased hunger, thirst, and frequent urination. If left untreated or improperly managed, it can lead to a plethora of complications [2, 3].

While hyperosmolar hyperglycemia, diabetic ketoacidosis, and even mortality are common acute complications of DM, severe chronic problems include cognitive impairment, retinal damage, nerve damage, foot ulcers, and chronic kidney disease [4].

DM is a global burden due to its high morbidity and mortality rates [5]. Around 463 million people are sufferings from DM, estimating to be 700 million by 2045 worldwide.
According to epidemiological research, diabetes is more common in middle- and low-income countries, with around half of the cases unreported and misdiagnosed [6, 7]. The most common types of diabetes are type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) (Figure 1). T2DM accounts for 90 to 95% of DM cases, with the remaining 5 to 10% being other types of DM, such as T1DM, gestational diabetes, and other small specialized varieties that are rarely encountered [8]. To minimize the annual death rate from T1DM and T2DM, cost-effective treatment options are being searched substantially [9]. Several anti-diabetic drugs are sometimes time-consuming due to not being single-dose treatment regimens; some must be taken for the rest of one’s life [10].

Preclinical findings suggested that dietary polyphenols with antidiabetic properties are available in fruits, vegetables, etc. [11]. A comprehensive systematic review found an association between a polyphenol-rich diet intake and reduced risk conditions of diabetes [12, 13]. Polyphenols have also appeared to improve glucose metabolism in clinical studies. For example, regular consumption of apple polyphenols for 12 weeks improved glucose tolerance in adults [14, 15]. Despite the fact that several pathways for antidiabetic properties of polyphenolic compounds have been hypothesized, mostly they are based on in vitro research with pharmaceutical doses, which frequently provide misleading or inconsistent outcomes [16, 17]. However, nanoformulations of polyphenols have been demonstrated to possess the potentiality for delivering naturally prevailing antidiabetic drugs with poor pharmacological properties compared with alternative dosage forms [18]. To improve the therapeutic potential by lowering the frequency of administration, increasing accessibility, and delivering prolonged attributes, the nanodrug delivery method is attracting growing interest in formulation of development studies [19–21].

Therefore, this review aimed to provide a clear-cut explanation of polyphenols and their nanoformulations that are used to treat DM with improved antidiabetic efficacy.

2. Bioavailability of Polyphenols

The primary sources of dietary polyphenols include fruits, vegetables, and beverages. Because bioactive components are particularly effective in the prevention of various ailments, it is critical to be aware of their availability. The proportion of nutrients is consumed, absorbed, and metabolized by typical gastrointestinal pathways [22, 23]. Intake of phenolic chemicals in large amounts has little effect on the bioavailability profile [24]. Rein and his colleagues [25] advocated that bioavailability is recognized as the final step in ensuring the bioeffectiveness of polyenolic compounds, such as at the dietary level, bioavailability is the proportion of a food that is consumed and digested and therefore a matter of nutritional efficacy. As a result, a number of other factors could obstruct the direct absorption of polyenolic compounds found in food. External features include interactions with other molecules, food digestion, and a variety of other intestinal functions [26, 27]. Similarly, bioavailability is affected by a variety of activities, including distribution, liberation, elimination, absorption, and metabolic phases, whereas limiting variables, such as intestinal level absorption, restrict bioavailability [25]. Gallic acid and low molecular weight isoflavones are easily absorbed through the gastrointestinal tract (GIT) [24]. Many phenolic compounds, on the other hand, are absorbed at a rate of 0.30–43% and have a low metabolite level circulating in the plasma [25]. Flavonols such as kaempferol and quercetin, on the other hand, have a variety of physiologic in vivo effects [28]. However, due to low absorption rates, low water solubility, and increased instability in alkaline and neutral environments, the bioavailability of these compounds as potential health-promoting components is limited [29]. Apigenin’s pure form is also limited in use due to its low solubility and instability [30]. Metabolic events in the oral cavity start the bioavailability of phenolic compounds found in diets. Mastication, for example, is vital in food preparation because it disrupts food components and releases chemicals. When glycosylated phenolic compounds come into contact with bacteria’s glycosidase enzymes, they begin to be processed in the oral cavity [31]. According to the research [32], oral microflora enzymes significantly processed anthocyanin detected in fruit extract high in phenolic components and human saliva. After passing through the stomach, just a few molecules are hydrolyzed, while many polyphenols are not. According to Correa-Betanzo and colleagues [33], the gut microbiota’s reaction was connected to the stability and change in these dietary components. To be absorbed, certain phenolic components in the GIT must undergo structural changes. Ex vivo studies have demonstrated that phenolic acid is absorbed in the GIT, such as the jejunum and colon, or at the gastric level [26, 34]. The phenolic compounds are assumed to be absorbed by a passive diffusion process or by gastrointestinal carriers such as P-glycoprotein and SGLT1 cotransporters. These transporters, which are expressed on the cell membrane, carry drugs into the cell interior [35, 36]. Aglycones, for example, can move through epithelial cell membranes via passive diffusion [31]. The colon was the site of the first passage reactions, which allowed prior chemical metabolism and, as a result, encouraged absorption. The portal vein transports these compounds from the colon to the liver, and plasma proteins disperse them throughout the bloodstream [37]. Meanwhile, phenolic chemicals are bio-transformed in the liver to make them more polar molecules, which will help with their excretion. Phase I involves oxidation and reduction, as well as hydrolysis events catalyzed by the CYP450 enzymes [35], while phase II enhances the hydrophilicity of the molecules prior to elimination [31, 38].

3. Causes and Complications of T1DM and T2DM

T1DM is caused by the death of insulin-producing beta cells in the pancreatic islets (Figure 2), resulting in insulin insufficiency. T1DM can be categorized as either idioptic or immune-mediated. Most T1DM is caused by immunological mediation, in which a T-cell-mediated autoimmune response results in the death of beta cells and, as a result,
The majority of those who are affected are otherwise healthy, having a normal weight at the time of beginning. Insulin sensitivity and responsiveness are frequently normal, especially in the early phases. Despite the fact that T1DM is typically referred to as "juvenile diabetes" due to its consistent beginning in children, the majority of persons with T1DM are now adults. T1DM may be accompanied by unpredictable, irregularly high blood sugar levels, as well as the risk of serious low blood sugar or diabetic ketoacidosis. T1DM patients with these symptoms account for 1–2% of the people [40]. T1DM is partly inherited, with various genes, including several human leukocyte antigen (HLA) genotypes, influencing the chance of developing the disease. Environmental variables, such as food, stress, or viral infection, may play a role in the beginning of DM in those who have a genetic predisposition. Despite the fact that several viruses have been documented, there is no convincing evidence that they can cause DM in humans [41, 42]. Gliadin (a gluten protein) has been described as a dietary factor in the development of T1DM, albeit the mechanism has not been elucidated, at least not completely [43]. T1DM can strike at any age; a considerable percentage of cases have been discovered in adults. T1DM in adults is known as latent autoimmune diabetes of adults (LADA), and it develops more slowly than T1DM in children [44]. Adults with latent autoimmune diabetes are frequently misdiagnosed as having T2DM at first, owing to their age rather than the cause [45].

T2DM, which accounts for 90 to 95% of all DM cases, is caused by insulin resistance, which may include a relative reduction in insulin production (Figure 3). Insulin receptors are thought to be linked to anomalies in the body’s sensitivity to insulin. Cases of DM with recognized faults are divided into two categories. Before developing T2DM, many people with T2DM have clinical signs of diabetes (such as poor glucose tolerance and/or impaired fasting glucose) [46]. Lifestyle medications/changes that improve insulin sensitivity or decrease glucose synthesis in the liver may be able to correct or slow the progression of prediabetes to overt T2DM [47]. T2DM is caused mostly by genetics, as well as lifestyle and environmental factors. Obesity (BMI > 30), urbanization, stress, poor diet, and a lack of physical activity are all variables that contribute to the development of T2DM. Dietary factors, such as sugar-sweetened beverages, have been associated with a greater risk of T2DM. Trans-fats and saturated fats raise hazards, while monounsaturated and polyunsaturated fats lessen risks [48]. Excessive eating of carbohydrate-dense foods such as white rice has been linked
to an increased risk of diabetes [49]. In certain people, a lack of or insufficient physical activity can raise their risk of developing diabetes.

4. Diabetic Status Influences the Bioavailability of Dietary Polyphenols

Hyperglycemia can affect the bioavailability of small-molecule drugs by affecting absorption, distribution, biotransformation, and excretion. In terms of daily dose, component complexity, and food interaction, the bioavailability of medications and dietary polyphenols differs. Polyphenols in food are poorly absorbed, digested, and eliminated. Only about 5–10% of polyphenols are absorbed, and more than 90% of polyphenols that are digested end up in the colon. Clinical drugs, on the other hand, are typically well absorbed and transported to the tissues they are intended to treat. Hyperglycemia has an impact on glucose, protein, and lipid metabolism. The mechanisms that control these metabolic processes are frequently involved in phytochemical biotransformation as well. As a result, hyperglycemia has an impact on dietary polyphenol bioavailability. $C_{\text{max}}$ and area under the curve (AUC) of mangiferin, baicalin, wogonoside, and oroxyloside were considerably greater in diabetic mice than in healthy mice [50–52]. Phlorizin bioavailability was significantly improved in T2DM rats [53]. Diabetic rats absorbed significantly higher levels of cynaroside, quercetin, luteolin, isorhamnetin, rutin, and formononetin than

Figure 2: Insulin-secreting cells located in the pancreatic islets of Langerhans. Type 1 (insulin-dependent) diabetes is caused by the immune system recognizing and targeting proteins on the surface of beta cells, possibly mistaking them for proteins on an invading organism. The sequence of events that leads to type 1 diabetes is intricate and poorly understood from there. Insulitis is produced by white blood cells known as cytotoxic or “killer” T cells invading the pancreatic islets and inflaming them. Over the course of years, the beta cells are gradually eliminated. Diabetes symptoms begin to appear after most of them have faded. Researchers seek to learn more about the immune system’s attack on beta cells in order to develop techniques to stop the process and prevent or delay the formation of diabetes.

Figure 3: Insulin resistance occurs when cells in the muscles, fat, and liver do not respond to insulin properly, preventing glucose absorption from the bloodstream. The pancreas produces more insulin as a result, assisting glucose absorption into the cells.
normal rats [54]. C_{max} values for catechin, epicatechin, quercetin, and resveratrol conjugated metabolites were reduced in Zucker diabetic fatty rats [55]. The bioavailability of methylation flavan-3-ol, resveratrol, and quercetin metabolite was dramatically reduced in Zucker diabetic fatty rats [55]. Furthermore, little progress has been made in hyperglycemia-induced changes in the bioavailability of bioactive phytochemicals. Understanding how hyperglycemia affects the bioavailability of dietary polyphenols will aid in improving the benefits and clinical consequences of these phytochemicals [56].

5. Polyphenolic Compounds and Their Properties against T1DM and T2DM

5.1. Curcumin. Curcumin (Figure 4), a polyphenol, is derived from the turmeric plant’s dried root (Curcuma longa). Curcumin contains a wide range of pharmacological effects, the most famous of which are anti-inflammatory and antioxidant capabilities [57, 58]. Hepatic stellate cells (HSCs) are the major players in T1DM- and T2DM-related hepatic fibrogenesis [59], and AGEs activate RAGE gene expression in HSCs, which may stimulate HSC activation [58, 59]. Curcumin oral therapy boosted plasma insulin levels, decreased blood glucose levels, and decreased body weight, according to a study [60]. Curcumin improved glucose/lipid metabolic imbalance and increased insulin resistance in diabetic rats, according to a study [61]. These results could be linked to a decrease in TNF-α and free fatty acid in serum [4]. Curcumin has antidiabetic properties in both T1DM and T2DM patients. Curcumin protects pancreatic islets from oxidative stress caused by streptozotocin by scavenging free radicals. Curcumin improved insulin secretion, islet viability, reduced reactive oxygen species (ROS) levels, and decreased nitric oxide (NO) production. Oral curcumin reduced hyperglycemia-induced kidney/liver damage in db/db mice by normalizing mitochondrial activity and decreased lipid peroxidation and NO production [62].

5.2. Resveratrol. Resveratrol (3,4′,5-trihydroxy-stilbene, RES) (Figure 4) is a naturally occurring phytoalexin occurring mostly in grains, fruits, vegetables, dry legumes, and plant-derived beverages such as tea, coffee, and wine. Antiobesity, antiadiposity, anticancer, anti-inflammatory, antioxidative, and cardiovascular-protective actions are mostly just a few of the biological and pharmacological characteristics of RES [63–66]. RES has been shown to have glucose-lowering benefits in both T1DM and T2DM in a vast number of in vivo studies. Generally, diabetes treatment focuses on lowering blood glucose levels, improving insulin sensitivity, and preserving pancreatic β-cells. All of these functions are covered by the protective effects of RES [67–69]. Moreover, multiple studies offered decent research on the therapeutic application of RES for the alleviation of diabetic problems [70].

5.3. Quercetin. Quercetin (Figure 4) is a natural flavonoid with antidiabetic effects [71] and the ability to pass the blood-brain barrier (BBB) [72]. Because the brain is one of the organs impacted by diabetes-induced hyperglycemia, dietary components that provide neuroprotection might help reduce the negative effects of the disease [73, 74]. Researchers discovered that quercetin could significantly improve hyperglycemia and insulin resistance [74]. The underlying mode of action was linked to a decrease in endoplasmic reticulum (ER) stress, oxidative stress, and β-cell death in the pancreas. Furthermore, many research studies on the use of quercetin in the treatment of DN have been undertaken. By suppressing TGF-β1 and connective tissue growth factor (CTGF) overexpression in the kidneys, quercetin could restore renal function in DN rats. Quercetin had the exact opposite effect on insulin-stimulated glucose transporter type 4 (GLUT4) translocation in both the baseline and insulin-resistant states, according to recent research [75].

5.4. Apigenin. Apigenin (Figure 4) is a flavone found in various fruits, vegetables, nuts, onions, oranges, and tea [75]. Although alloxan caused an increase in blood cholesterol, hepatic lipid peroxidation, and a decrease in the activity of cellular antioxidants such as catalase (CAT), superoxide dismutase (SOD), and glutathione (GSH), apigenin treatment of diabetic mice alleviated hyperglycemia and improved antioxidants [76]. Apigenin inhibited parathyroid hormone-related protein-stimulated increases in messenger RNA expression levels of extracellular matrix proteins such as collagen 1A1 and fibronectin, proliferating cell nuclear antigen transforming growth factor β (TGF-β), and interleukin 6 (IL-6) in human pancreatic stellate cells [77, 78]. In streptozotocin (STZ)-induced diabetic rats, apigenin restores the cellular architecture of essential tissues to normal. Additionally, increased glucose transporter type 4 (GLUT4) translocation in response to apigenin therapy supports increased glucose reduction and β-cell preservation efficacy [79, 80].

5.5. Baicalein. Baicalein (Figure 4), a flavonoid derived from the roots of Scutellaria baicalensis Georgi and the fruits of Oroxylum indicum (L.) Benth, has been found to have strong antioxidant properties [81, 82]. Fu et al. [83] used a high-fat diet (HFD) and low dosages of STZ to develop diabetes in mice and then fed them an HFD with 0.25 or 0.5 g baicalein/kg diet. Diabetic mice given baicalein had considerably improved hyperglycemia, according to the researchers. They support screening and preclinical research of hydroxyflavones, particularly those with a better pharmacological profile, as prospective treatments for diabetes and their problems [84]. Baicalein also inhibited nuclear factor kappa B (NF-κB) activation, lowered inducible nitric oxide synthase (iNOS) and TGF-β1 expression, and improved the structural alterations in renal tissues [85]. Treatment with baicalein also lowered the levels of advanced glycation end products (AGEs) and tumour necrosis factor-alpha (TNF-α), decreased NF-κB activation, and prevented histopathological alterations, according to previous findings [86]. Upregulation of AMP-activated protein kinase (AMPK) and its associated signal pathway was the mechanism of action.
AMPK is a master regulator of metabolic balance involving inflammation and oxidative stress.

5.6. Luteolin. Lutein (Figure 4) is abundant in celery, parsley, broccoli, onion leaves, and chrysanthemum blooms, among other vegetables and fruits [87]. In 3T3-L1 adipocytes and primary mouse adipose cells, luteolin potentiates insulin action and enhances peroxisome proliferator-activated receptor (PPAR) expression and transcriptional activity, and the expression of PPAR target genes such as adiponectin, leptin, and GLUT4, and a PPAR antagonist inhibits this induction [88]. The decrease in circulation levels of inflammatory mediators such as monocyte chemoattractant protein 1 (MCP-1) and resistin, as well as the increase in adiponectin levels in obese mice, is likely to be managed by luteolin’s beneficial effects on metabolic pathways implicated in insulin resistance and DM pathogenesis [89]. In diabetic nephropathy, the mechanism of luteolin’s renoprotective property could be associated with increased heme oxygenase 1 (HO-1) expression and antioxidant levels [90]. Inflammation-related endothelial insulin resistance was alleviated by luteolin in an IKKb/IRS-1/Akt/eNOS-dependent pathway [91]. Luteolin enhanced insulin production in uric acid-damaged pancreatic β-cells by reducing MafA, which decreases mostly via the NF-κB and iNOS-NO signaling pathway [92].

5.7. Morin. Prunus dulcis (Mill.) D.A. Webb, fruits, and wine were shown to contain morin, a natural flavonoid and a prominent component of traditional medicinal herbs [93, 94]. Oral treatment of morin (Figure 4) for 30 days alleviated hyperglycemia, glucose intolerance, and insulin resistance in animal models. In diabetic rats treated with the morin, high levels of lipid peroxides were reduced, and antioxidant competence was increased. Following treatment, the lipid and lipoprotein profile in the serum was normalized. TNF-α levels were reduced after morin treatment [95]. Morin was reported to alleviate high fructose-induced hepatic SphK1/S1P signaling pathway impairment in rat liver and BRL3A cells, resulting in a decrease in hepatic NF-κB activation with IL-1β, IL-6, and TNF-α levels [96]. Morin then restored hepatic insulin and leptin sensitivity, followed by a reduction in hyperlipidemia and liver lipid buildup in animal and cell line models [97]. Dietary morin inhibitor of PTP1B acts as an insulin receptor activator and sensitizer, activating metabolic pathways [98]. Therefore, in these metabolic actions, morin may have a wide range of beneficial effects in the prevention and management of diabetes.

5.8. Catechin. Green tea contains catechin (Figure 4), a natural nonenzymatic plant antioxidant. Tea can quench thirst, calm the mind, function as a diuretic, and be used to treat coughing, weariness, and light sleep, according to ancient Chinese reports; it also contains anti-inflammatory, detoxifying, and expectorant-like qualities. Catechin has been shown to inhibit inflammatory cytokines and activate AMP-dependent/activated protein kinase [99], protein kinase B (Akt) [100], ERK/JNK-p53, and other signaling pathways to maintain normal mitochondrial respiratory
chain operation and exert specific therapeutic effects on diabetes in many studies [101]. Catechin also inhibited glucose-degrading enzymes, which helped to prevent diabetes. Catechin not only has distinct antihyperglycemic and antihyperlipidemic properties, but it also has specialized inhibitory effects on diabetes-related comorbidities, particularly DN [102–105]. Catechin was found to serve an important function in the prevention and management of diabetic cataracts. This compound could lower diabetic rat blood sugar levels, improve the expression of HSP27, MDR 2, and MDR3 mRNA in the lens tissue, and prevent and control diabetic retinal cataracts [106–108]. Thus, catechin could be used to develop medications or auxiliary drugs for the treatment of diabetes. Catechin, in particular, protects DNA and reduces oxidative damage, which is a typical entrance site for diabetes and cancer treatment and has significant medical research value.

5.9. Naringenin. Naringin (Figure 4), a flavonoid found in grapefruits and citrus fruits, is a common flavonoid. Its antihyperglycemic, antioxidant, and anti-inflammatory effects are well-known [109]. Several recent studies have shown that naringin can help with T1DM and T2DM, as well as the severity of their related health issues; the mechanism is unknown [109, 110]. In vitro studies have shown that naringin prevents cells from being destroyed by high glucose levels. Furthermore, naringin has been shown to have therapeutic effects on diabetic complications in multiple studies [111, 112]. Naringin protected rats with HFD/STZ diabetes from diabetes-induced anemia by increasing adiponectin expression and decreasing pro-inflammatory cytokine production. Naringin significantly improved serum glucose levels and lipid profile in rats with NA/STZ-induced DM [109]. In addition to reducing oxidative stress, the effects could be amplified by increasing glycogen phosphorylase and hepatic G6Pase activities, improving insulin secretion response, and promoting GLUT4 expression, adiponectin, and insulin receptor [109].

6. Nanoformulations in Diabetes Treatment

6.1. Curcumin. Due to its efficacy against T2DM, curcumin has been utilized in food and medicine in Asia for centuries [113–116]. Due to its low water solubility and gastrointestinal stability, it has limited potential for oral delivery [117–121]. Nanodelivery technologies are a different strategy that can increase the stability of those molecules while also increasing curcumin bioavailability [122–131]. Curcumin-loaded PLGA nanoparticles (NPs) with a particle size of 281 nm have been demonstrated to have a better bioavailability when given orally in a diabetic rat model, delaying cataract formation [132]. The self-nano-emulsifying curcumin delivery system was synthesized, with a particle size of 213 nm, and has been proven to increase diabetic neuropathy protection in male Sprague Dawley rats using oral administration systems [133, 134]. A curcumin-loaded NP was recently discovered to have better bioavailability at lower dosage levels [135]. Curcumin-loaded PLGA NP with a particle size of 158 nm was synthesized for oral delivery in another investigation, and it showed improved solubility and bioavailability. Nanoformulated curcumin had a 22-fold improvement in oral bioavailability compared with traditional curcumin [136]. Curcumin nano-micelles with a particle size of 17 nm were also created for oral delivery and demonstrated 2 times increase in bioavailability [137].

6.2. Resveratrol. Chemical changes, the addition of bio-enhancers, the production of RES prodrugs, and the development of innovative pharmaceutical preparations are all alternatives for addressing RES’s pharmacological ineptitude [21, 22, 138]. Nanoencapsulation of RES has been shown to be superior to other methods in terms of stability, bioavailability, selective targeting, and increased therapeutic response [138, 139]. RES-loaded layer-by-layer formulations could be used to deliver RES as a medication [140]. In glucose or STZ-treated β-TC cells, multilayered RES nanoliposomes produced by dry film hydration and their PEG-amalgamated (PEGylated) modification have been shown to enhance glycaemic status and insulin level. When compared to pure RES, the preparations had a persistent impact in vitro for up to 24 hours [141]. In glucose or STZ-exposed β-TC cells, resveratrol-loaded nanocochleates produced similar results [142]. As a result, RES-loaded nanoliposomes, PEGylated RES-loaded nanoliposomes, and RES-loaded nanocochleates may be useful formulations for the treatment of T2DM and its microvascular complications [141, 142]. The formulation of RES-loaded casein NPs was proven to be an excellent strategy for the oral delivery of RES, fast penetration, and prolonged drug release. This formulation has been exhibited to enhance resveratrol oral bioavailability by 10-fold [143]. In diabetic rats, RES-loaded solid lipid NPs were found to increase the therapeutic impact of RES after oral administration. Under normal settings, the formulation is allowed for an initial burst followed by a steady release, improving RES oral bioavailability. The formulation was demonstrated to be more efficient than free RES at reversing insulin resistance in T2DM rat sera [143]. Galactosylated PLGA has also been discovered to be a promising nanocarrier for RES oral delivery to increase bioavailability and therapeutic efficacy [144]. In the retina of diabetic rats, oral treatment with RES-assembled gold nanoparticles (AuNPs) inhibited the activation of vascular endothelial growth factor (VEGF) 1, monocyte chemotactic protein 1 (MCP-1), intercellular adhesion molecule 1 (ICAM-1), extracellular signal-regulated kinase (ERK) 1/2, NF-κB, TNF-α, IL-6, and IL-1β genes. Therefore, RES-assembled AuNPs could be used to treat diabetic retinopathy [145]. There has yet to be a report on a diabetic human clinical trial with RES nanoformulation.

6.3. Quercetin. Quercetin nanofabrication has opened up novel potentialities for enhancing oral bioavailability, target selectivity, therapeutic efficacy, and compliance. The oral bioavailability of quercetin loaded on PLGA NPs was shown to be five times higher than untreated quercetin. This quercetin nanoformulation provided up to 6 days of
quercetin release. Quercetin-PLGA NPs were reported to dramatically reverse hyperglycemia and oxidative stress (kidney and pancreas) in diabetic rats at a dose of 150 mg/kg every fifth day, and at a level of 150 mg/kg/day, the efficacy was shown to be higher than that of pure quercetin [146]. In diabetic mice, quercetin nanorods provided effective quercetin distribution with superior pharmacological properties in reversing hyperglycemia, alterations in glucose-metabolizing enzymes, and oxidative stress. Nanorods have been shown to improve diabetes treatment efficiency by increasing cellular absorption and bio-distribution of quercetin in the target areas [147]. In PEG-PLA with quercetin in rats, nanocarriers significantly improved the therapeutic potential of quercetin compared with free quercetin in the control of diabetes and associated nephropathy by increasing quercetin serum content [148]. When compared to native oral quercetin, oral distribution of quercetin-succinylated chitosan-alginate core-shell-corona-shaped NPs significantly enhanced oral hypoglycemic properties of quercetin in diabetic rats [149]. In the therapy of diabetes in rats, quercetin-loaded Soluplus micelles were reported to enhance oral bioavailability (≥16%) and preserve a sustained release pattern [150]. When compared to free quercetin, oral administration of quercetin-conjugated superparamagnetic iron oxide nanoparticles improved diabetes-induced memory impairment in rats at a substantially lower dose [151]. Several quercetin nanoformulations have been reported to enhance oral bioavailability and therapeutic effects against diabetes; nevertheless, clinical findings on quercetin nanoformulation’s antidiabetic potential have yet to be published.

6.4. Apigenin. Several nanoformulations have been developed to improve apigenin’s medicinal efficacy, which has not only increased bioavailability but also confirmed selective targeting. Microwave-synthesized apigenin-pluronic F127 NPs were reported to boost apigenin dissolution rate and oral absorption by more than threefold when compared to the marketed capsule [151]. Apigenin’s stability and bioavailability were increased using a carbon nanopowder-based solid dispersion [152]. Apigenin-loaded nanoliposomes have been shown to prevent cardiac cell death in diabetic cardiomyopathy rats [153].

6.5. Baicalin. Baicalin is a new antidiabetic bioactive chemical identified exclusively in scutellaria plants, and it has promising bioactivity against T2DM [154, 155]. These bioactive compounds are quite hydrophobic, which limits their bioavailability and, as a result, their functional activity through oral administration systems [156, 157]. Using a nanostructured lipid carrier (NLC) delivery system, a nano-based delivery technique was recently used to increase bioavailability. It demonstrated stronger antidiabetic action than traditional baicalin, limiting medication dose levels [158]. The bioavailability of a baicalin nanoemulsion delivered orally was also studied. The bioavailability of a baicalin-loaded nanoemulsion was shown to be seven times higher than that of the free suspension, suggesting that it could be effective for a variety of therapies, including T2DM. The storage stability of the baicalin-loaded nanoemulsion was also investigated for 6 months, with the results indicating that a uniform particle size provided improved stability [159]. Baicalin-loaded nanoliposomes with a particle size of 375 nm were found to have better bioavailability in a variety of target organs, such as the kidney, liver, and pancreas, in another study [160].

6.6. Luteolin. The oral bioavailability of luteolin has been demonstrated to be improved by luteolin nanoformulation [161, 162]. Luteolin-assembled poly (ε-caprolactone)-PLGA–nature oil has been proven to be a decent nanocarrier for boosting luteolin dispersion in water and thereby improving oral bioavailability [162]. Luteolin-loaded solid lipid NPs have been shown to improve luteolin’s solubility and hence its therapeutic efficacy [163].

6.7. Morin. Morin is a phyto-derived bioflavonoid found in many fruits, vegetables, and herbs, and it has been demonstrated to have numerous anti-diabetic and anti-diabetic properties [164, 165]. Lipogenesis and inflammation are all potential actions. Morin has also been shown to have a stronger hepatoprotective action in some trials, implying that it can lower hyperlipidemia. Morin also has an insulin-mimetic effect and is generally recognized as a naturally produced anti-diabetic drug [98, 166]. Its bioavailability is reduced due to its poor oral solubility, resulting in fewer effects. A greater dosage, on the other hand, may cause toxicity. Novel nanodelivery techniques have been researched to enhance bioavailability by oral delivery to overcome such disadvantages [167–169]. Morin-loaded self-nanoemulsifying nanodelivery devices have recently been designed and investigated for oral bioavailability. The enhanced oral bioavailability of these substances has been linked to increased bioactivity in the treatment of a variety of chronic illnesses [168]. Morin was successfully produced utilizing mixed micelles with a particle size of 90 nm in another method. When compared to native substances, the nanosized morin-loaded mixed micelles demonstrated a 3.6-fold increase in cellular absorption, with a 2.4-fold higher permeability rate, which improves bioavailability in systemic circulation [170]. Morin-loaded solid lipid NPs were tested for their usefulness in oral bioavailability in a different way, indicating that a smaller particle size enhances the permeability of the chemical across an intestinal membrane, resulting in a longer release of the compound. Several successful nanotechnology approaches have been employed to increase morin bioavailability during oral delivery, allowing researchers to investigate its promising chronic illness models such as T2DM and its related conditions [171].

6.8. Catechins. Catechin nanoscale formulations have previously been shown to increase catechin stability, gastrointestinal absorption, and bioaccumulation [172–177]. In terms of α-glucosidase and α-amylase inhibitory activities, catechin-grafted inulin was found to have better antidiabetic
potential than free catechins and acarbose [178, 179]. Furthermore, catechin-grafted chitosan NPs outperformed native catechins in terms of antioxidant activity [178]. Epigallocatechin-3-gallate-loaded chitosan-peptide NPs have better cellular absorption and antioxidant capacity than free epigallocatechin-3-gallate [180]. Epigallocatechin gallate-loaded cationic lipid NPs have been shown to have promising benefits in reducing ocular inflammation and oxidative stress, indicating that epigallocatechin-3-gallate is likely helpful in diabetes complications [181]. Furthermore, self-assembled gelatin-epigallocatechin gallate NPs were discovered to significantly reduce ocular angiogenesis by targeting integrin αvβ3 [182]. The effective effects of catechins nanoformulations against diabetes and associated problems were predicted in the aforementioned findings. However, to obtain improved therapeutic management in diabetes, more study is needed to produce a unique catechin nanoformulation.

6.9. Naringenin. Naringenin is a flavonoid component found in various citrus fruits and beverages, and it has been demonstrated to have powerful antidiabetic properties in a variety of cellular and animal [183–185]. They are often employed to make innovative beverages due to their higher potential activity in several chronic conditions [186, 187]. A naringenin-based nanoemulsion with a particle size of 50 nm was produced, demonstrating increased naringenin bioavailability by oral delivery. The increased bioavailability of naringenin was most likely owing to its improved solubility in self-emulsion nanodelivery devices, which can help it be used more effectively in therapy [186]. Naringenin-loaded NPs with a mean particle size of 66 nm were created, and they had a better bioavailability when administered orally, resulting in improved hepatoprotective efficacy in rat models [188]. In another work, researchers created naringenin-loaded chitosan nanoparticles with a particle size of 407 nm, which had 70% encapsulation effectiveness and increased antioxidant action in in vitro cell models. Although numerous nanodelivery techniques have been tested for oral bioavailability in a variety of illness models, their potential for T2DM animal models and disorders is still restricted [189].

7. Conclusion and Future Perspectives

Long-term treatment is essential in the event of chronic metabolic syndrome, such as diabetes. Patient compliance is thus the most significant factor in the development of pharmacotherapeutic drugs for diabetes control. Antidiabetic polyphenolic compounds have a lot of potential for lowering diabetes and its complications. The biochemical and pharmacokinetic properties of polyphenols limit their therapeutic usefulness. Many antidiabetic nanoformulations have been developed using polyphenolic compounds and nanocrystals. Furthermore, by overcoming pharmacokinetic and biopharmaceutical limitations, nanoscale formulations of polyphenol antidiabetic drugs have been shown to improve therapeutic outcomes. Therefore, nanoformulation development might be seen as a promising approach for achieving the greatest clinical output of polyphenolic antidiabetic compounds. However, more research is required to build clinically potential therapeutic nanoformulations of polyphenolic antidiabetic compounds for the treatment of diabetes and its complications.

Data Availability

All data used to support the findings of this study are included in the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] A. Quazi, M. Patwekar, F. Patwekar et al., “In vitro alpha-amylase enzyme assay of hydroalcoholic polyherbal extract: proof of concept for the development of polyherbal teabag formulation for the treatment of diabetes,” Evidence-Based Complementary and Alternative Medicine, vol. 2022, Article ID 1577957, 7 pages, 2022.
[2] M. M. Rahman, M. R. Islam, S. Shohag et al., “The multifunctional role of herbal products in the management of diabetes and obesity: a comprehensive review,” Molecules, vol. 27, 2022.
[3] M. F. Mahomoodyally, D. Lobine, M. C. N. Picot-Allain, N. Sadeer, S. Jugreer, and G. Zengin, “Conventional and non-conventional targets of natural products in the management of diabetes mellitus and associated complications,” Current Medicinal Chemistry, vol. 28, no. 23, pp. 4638–4669, 2021.
[4] S. Mitra, F. Islam, R. Das et al., “Pharmacological potential of Avicennia alba leaf extract: an experimental analysis focusing on antidiabetic, anti-inflammatory, analgesic, and antidiarrhoeal activity,” BioMed Research International, vol. 2022, Article ID 7624189, 10 pages, 2022.
[5] B. Emran, M. Dutta, M. M. N. Uddin, A. K. Nath, and M. Z. Uddin, “Antidiabetic potential of the leaf extract of Centella asiatica in alloxan induced diabetic rats,” Jahan-girnagar University Journal of Biological Sciences, vol. 4, pp. 51–59, 2015.
[6] F. Islam, S. Mitra, M. H. Nafady et al., “Neuropharmacological and antidiabetic potential of laneea coromandelica (houtt.) merr. Leaves extract: an experimental analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2022, Article ID 614733, 10 pages, 2022.
[7] A. Quazi, M. Patwekar, F. Patwekar, A. Mezni, I. Ahmad, and F. Islam, “Evaluation of wound healing activity (excision wound model) of ointment prepared from infusion extract of polyherbal tea bag formulation in diabetes-induced rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2022, p. 7, Article ID 1372199, 2022.
[8] B. Andrei Cristian and P. Amorin Remus, “Diabetic neuropathy prevalence and its associated risk factors in two representative groups of type 1 and type 2 diabetes mellitus patients from bihoro county,” Medicina (Bucharest), vol. 13, no. 3, pp. 229–234, 2018.
[9] M. Evans, R. Mehta, J. Gundgaard, and B. Chubb, “Cost-effectiveness of insulin degludec vs. Insulin glargine U100 in type 1 and type 2 diabetes mellitus in a UK setting,” Diabetes Therapy, vol. 9, no. 5, pp. 1919–1930, 2018.
Evidence-Based Complementary and Alternative Medicine

[10] T. Battelino, R. Tehranchi, T. Bailey et al., “Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: results of a phase 3, randomized controlled trial,” Pediatric Diabetes, vol. 22, no. 5, pp. 734–741, 2021.

[11] N. Tran, B. Pham, and L. Le, “Bioactive compounds in anti-diabetic plants: from herbal medicine to modern drug discovery,” Biology, vol. 9, no. 9, p. 31–31, 2020.

[12] S. Mitra, A. M. Tareq, R. Das et al., “Polyphenols: A first evidence in the synergism and bioactivities,” Food Reviews International, vol. 38, 2022.

[13] M. M. Rahman, F. Islam, S. Afsana Mim et al., “Multi-functional roles and pharmaceutical potential of dietary flavonoid narirutin,” Biomedicine & Pharmacotherapy, vol. 150, Article ID 112932, 2022.

[14] T. L. Launholt, C. B. Kristiansen, and P. Hjorth, “Safety and side effects of apple vinegar intake and its effect on metabolic parameters and body weight: a systematic review,” European Journal of Nutrition, vol. 59, no. 6, pp. 2273–2289, 2020.

[15] S. Mitra, J. Anjum, M. Muni et al., “Exploring the journey of emodin as a potential neuroprotective agent: novel therapeutic insights with molecular mechanism of action,” Biomedicine & Pharmacotherapy, vol. 149, Article ID 112877, 2022.

[16] A. Da Porto, A. Cavarape, G. Colussi, V. Casarsa, C. Catena, and L. A. Sechi, “Polyphenols rich diets and risk of type 2 diabetes,” Nutrients, vol. 13, no. 5, 2021.

[17] P. Kesharwani, B. Gorain, S. Y. Low et al., “Nanotechnology based approaches for anti-diabetic drugs delivery,” Diabetologia Research and Clinical Practice, vol. 136, pp. 52–77, 2018.

[18] M. M. Rahman, F. Islam, S. Afsana Mim et al., “Multi-functional therapeutic approach of nanomedicines against inflammation in cancer and aging,” Journal of Nanomaterials, vol. 2022, Article ID 4217529, 19 pages, 2022.

[19] H. Chopra, S. Bibi, A. K. Mishra et al., “Nanomaterials: a promising therapeutic approach for cardiovascular diseases,” Journal of Nanomaterials, vol. 2022, Article ID 4155729, 25 pages, 2022.

[20] H. Chopra, S. Bibi, F. Islam et al., “Emerging trends in the delivery of resveratrol by nanostructures: applications of nanotechnology in life sciences,” Journal of Nanomaterials, vol. 2022, Article ID 3083728, 17 pages, 2022.

[21] F. Islam, J. F. Khadja, M. Harun-Or-Rashid et al., “Bioactive compounds and their derivatives: an insight into prospective phytotherapeutic approach against alzheimer’s disease,” Oxidative Medicine and Cellular Longevity, vol. 2022, Article ID 5100904, 22 pages, 2022.

[22] M. M. Rahman, S. Bibi, M. S. Rahaman et al., “Natural therapeutics and nutraceuticals for lung diseases: traditional significance, phytochemistry, and pharmacology,” Biomedicine & Pharmacotherapy, vol. 150, Article ID 113041, 2022.

[23] J. M. Carbonell-Capella, M. Buniwksa, F. J. Barba, M. J. Esteve, and A. Frigola, “Analytical methods for determining bioavailability and bioaccessibility of bioactive compounds from fruits and vegetables: a review,” Comprehensive Reviews in Food Science and Food Safety, vol. 13, no. 2, pp. 155–171, 2014.

[24] M. J. Rein, M. Renouf, C. Cruz-Hernandez, L. Actis-Goreta, S. K. Thakkar, and M. da Silva Pinto, “Bioavailability of bioactive food compounds: a challenging journey to bioefficacy,” British Journal of Clinical Pharmacology, vol. 75, no. 3, pp. 588–602, 2013.

[25] M. R. Islam, F. Islam, M. H. Nafady et al., “Natural small molecules in breast cancer treatment: understandings from a therapeutic viewpoint,” Molecules, vol. 27, no. 7, p. 2165, 2022.

[26] M. D’Archivio, C. Filesi, R. Vari, B. Scazzocchio, and R. Masella, “Bioavailability of the polyphenols: status and controversies,” International Journal of Molecular Sciences, vol. 11, no. 4, pp. 1321–1342, 2010.

[27] M. R. Islam, M. J. Uddin, A. A. Reza, A. M. Tareq, T. B. Emran, and J. Simal-Gandara, “Ethnomedicinal value of
Evidence-Based Complementary and Alternative Medicine

antidiabetic plants in bangladesh: A comprehensive review,” *Plants, vol. 10, p. 729, 2021.*

[43] J. C. Antvorskov, K. Josefson, K. Engkilde, D. P. Funda, and K. Buschard, “Dietary gluten and the development of type 1 diabetes,” *Diabetologia,* vol. 57, no. 9, pp. 1770–1780, 2014.

[44] S. Carlsson, “Etiology and pathogenesis of latent autoimmune diabetes in adults (LADA) compared to type 2 diabetes,” *Frontiers in Physiology,* vol. 10, p. 320, 2019.

[45] E. Laugesen, J. A. Østergaard, and R. D. G. Leslie, “Latent autoimmune diabetes of the adult: current knowledge and uncertainty,” *Diabetic Medicine,* vol. 32, no. 7, pp. 843–852, 2015.

[46] “Pharmacologic approaches to glycemic treatment,” *Diabetes Care,* vol. 40, no. 1, pp. S64–S74, 2017.

[47] N. W. Carris, R. R. Magness, and A. J. Labovitz, “Prevention of diabetes mellitus in patients with prediabetes,” *The American Journal of Cardiology,* vol. 123, no. 3, pp. 507–512, 2019.

[48] J. A. Edge, M. E. Ford-Adams, and D. B. Dunger, “Causes of death in children with insulin dependent diabetes 1990–1996,” * Archives of Disease in Childhood,* vol. 81, no. 4, pp. 318–323, 1999.

[49] E. A. Hu, A. Pan, V. Malik, and Q. Sun, “White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review,” *BMJ,* vol. 344, p. 7851, 2012.

[50] F. Islam, M. Faysal, T. A. Trina et al., “Phytochemical screening and anthelmintic activity of alcoholic extract of fruits of Eleocharis dulcis,” *Pharmacologyonline,* vol. 3, pp. 94–99, 2019.

[51] F. Islam, N. F. Fahim, T. A. Trina, and I. J. Mishu, “Evaluation of antioxidant, antimicrobial and thrombolytic activity of eleocharis dulcis (Cyperaceae) fruits of methanol extract,” *Pharmacologyonline,* vol. 2, pp. 39–49, 2019.

[52] A. K. A. Fahadul Islam, S. I. Saiful, N. J. Sugandha, and S. I. I. Susmita Saha, “Phytochemical investigation and comparative anthelmintic activity of between methanol and acetone extract of limonia acidissima I (Fruit peel),” *Pharmacologyonline,* vol. 2, pp. 241–246, 2019.

[53] Z. Wang, Z. Gao, A. Wang et al., “Comparative oral and intravenous pharmacokinetics of phlorizin in rats having type 2 diabetes and in normal rats based on phase II metabolism,” *Food & Function,* vol. 10, no. 3, pp. 1582–1594, 2019.

[54] B. Bin Wei, Z. X. Chen, M. Y. Liu, and M. J. Wei, “Development of a UPLC-MS/MS method for simultaneous determination of six flavonoids in rat plasma after administration of maydis stigma extract and its application to a comparative pharmacokinetic study in normal and diabetic rats,” *Molecules,* vol. 22, no. 8, 2017.

[55] T. Y. Chen, M. G. Ferruzzi, Q. L. Wu et al., “Influence of diabetes on plasma pharmacokinetics and brain bioavailability of grape polyphenols and their phase II metabolites in the Zucker diabetic fatty rat,” *Molecular Nutrition & Food Research,* vol. 61, no. 10, 2017.

[56] C. Sun, C. Zhao, E. C. Guven et al., “Dietary polyphenols as antidiabetic agents: advances and opportunities,” *Food Frontiers,* vol. 1, no. 1, pp. 18–44, 2020.

[57] M. M. Rahaman, A. Rakib, S. Mitra et al., “The genus curcuma and inflammation: overview of the pharmacological perspectives,” *Plants (Basel, Switzerland),* vol. 10, no. 1, pp. 1–19, 2020.

[58] J. Lin, Y. Tang, Q. Kang, and A. Chen, “Curcumin eliminates the inhibitory effect of advanced glycation end-products (AGEs) on gene expression of AGE receptor-1 in hepatic stellate cells in vitro,” *Laboratory Investigation,* vol. 92, no. 6, pp. 827–841, 2012.

[59] J. Lin, Y. Tang, Q. Kang, Y. Feng, and A. Chen, “Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARγ activity and attenuating oxidative stress,” *British Journal of Pharmacology,* vol. 166, no. 8, pp. 2212–2227, 2012.

[60] M. M. Rahaman, A. Rakib, S. Mitra et al., “The genus curcuma and inflammation: overview of the pharmacological perspectives,” *Plants,* vol. 10, no. 1, pp. 1–19, 2021.

[61] L. Qing Su, Y. Di Wang, and H. Yan Chi, “Effect of curcumin on glucose and lipid metabolism, FFAs and TNF-α in serum of type 2 diabetes mellitus rat models,” *Saudi Journal of Biological Sciences,* vol. 24, no. 8, pp. 1776–1780, 2017.

[62] M. G. Soto-Urquieta, S. López-Briones, V. Pérez-Vázquez, A. Saavedra-Molina, G. A. González-Hernández, and J. Ramírez-Emiliano, “Curcumin restores mitochondrial functions and decreases lipid peroxidation in liver and kidneys of diabetic db/db mice,” *Biological Research,* vol. 47, no. 1, 2014.

[63] S. Cho, K. Namkong, M. Shin et al., “Cardiovascular protective effects and clinical applications of resveratrol,” *Journal of Medicinal Food,* vol. 20, no. 4, pp. 323–334, 2017.

[64] T. Meng, D. Xiao, A. Muhammed, J. Deng, L. Chen, and J. He, “Anti-inflammatory action and mechanisms of resveratrol,” *Molecules,* vol. 26, no. 1, 2021.

[65] M. Elshaer, Y. Chen, X. J. Wang, and X. Tang, “Resveratrol: an overview of its anti-cancer mechanisms,” *Life Sciences,* vol. 207, pp. 340–349, 2018.

[66] D. D. Huang, G. Shi, Y. Jiang, C. Yao, and C. Zhu, “A review on the potential of Resveratrol in prevention and therapy of diabetes and diabetic complications,” *Biomedicine & Pharmacotherapy,* vol. 125, Article ID 109767, 2020.

[67] K. Szukeldeska, M. Okulicz, and T. Szukeldeski, “Resveratrol reduces excessive cholesterol accumulation in Goto-Kakizaki rat, a model with congenital type 2 diabetes,” *Journal of Physiology & Pharmacology,* vol. 71, no. 4, pp. 581–587, 2020.

[68] X. Zhu, C. Wu, S. Qiu, X. Yuan, and L. Li, “Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis,” *Nutrition and Metabolism,* vol. 14, no. 1, 2017.

[69] E. Öztürk, A. K. K. Arslan, M. B. Yerer, and A. Bishaye, “Resveratrol and diabetes: a critical review of clinical studies,” *Biomedicine & Pharmacotherapy,* vol. 95, pp. 230–234, 2017.

[70] M. A. Darwish, A. M. Abo-Youssef, B. A. S. Messenha, A. A. Abo-Saif, and M. S. Abdel-Bakky, “Resveratrol inhibits macrophage infiltration of pancreatic islets in streptozotocin-induced type 1 diabetic mice via attenuation of the CXCL16/NF-κB p65 signaling pathway,” *Life Sciences,* vol. 272, 2021.

[71] E. J. Sohn, J. M. Kim, S. H. Kang et al., “Restoring effects of natural anti-oxidant quercetin on cellular senescent human dermal fibroblasts,” *American Journal of Chinese Medicine,* vol. 46, no. 4, pp. 853–873, 2018.

[72] A. Ishisaka, S. Ichikawa, H. Sakakibara et al., “Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats,” *Free Radical Biology and Medicine,* vol. 51, no. 7, pp. 1329–1336, 2011.

[73] H. H. Gaballah, S. S. Zakaria, S. E. Mwafy, N. M. Tahoon, and A. M. Ebeid, “Mechanistic insights into the effects of quercetin and/or GLP-1 analogue liraglutide on high-fat
diet/streptozotocin-induced type 2 diabetes in rats,” *Biomedicine & Pharmacotherapy*, vol. 92, pp. 331–339, 2017.

[74] M. S. Sandeep and C. D. Nandini, “Influence of quercetin, naringenin and berberine on glucose transporters and insulin signalling molecules in brain of streptozotocin-induced diabetic rats,” *Biomedicine & Pharmacotherapy*, vol. 94, pp. 605–611, 2017.

[75] P. Bin Lai, L. Zhang, and L. Y. Yang, “Quercetin ameliorates diabetic nephropathy by reducing the expressions of transforming growth factor-β1 and connective tissue growth factor in streptozotocin-induced diabetic rats,” *Renal Failure*, vol. 34, no. 1, pp. 83–87, 2012.

[76] S. Panda and A. Kar, “Apigenin (4′, 5, 7-trihydroxyflavone) regulates hyperglycaemia, thyroid dysfunction and lipid peroxidation in alloxaan-induced diabetic mice,” *Journal of Pharmacy and Pharmacology*, vol. 59, no. 11, pp. 1543–1548, 2007.

[77] A. A. Mrazek, L. J. Porro, V. Bhatia et al., “Apigenin attenuates 2-deoxy-D-ribose-induced oxidative cell damage in HIT-T15 pancreatic .BETA.-Cells.” *Biological and Pharmaceutical Bulletin*, vol. 35, no. 1, pp. 121–126, 2012.

[78] A. Akter, F. Islam, S. Bepary et al., “CNS depressant activities of Averrhoa carambola leaves extract in thiopental-sodium model of Swiss albino mice: implication for neuro-modulatory properties,” *The Biologist*, vol. 77, 2022.

[79] C. M. Hassain, M. K. Ghosh, B. S. Satapathy, N. S. Dey, and B. Mukherje, “Apigenin causes biochemical modulation, GLUT4 and CD38 alterations to improve diabetes and to protect damages of some vital organs in experimental dia-betes,” *American Journal of Pharmacology and Toxicology*, vol. 9, no. 1, pp. 39–52, 2014.

[80] Y. O. Kim, K. Leem, J. Park et al., “Cytoprotective effect of Scutellaria baicalensis in CA1 hippocampal neurons of rats after global cerebral ischemia,” *Journal of Ethnopharmacology*, vol. 77, no. 2–3, pp. 183–188, 2001.

[81] P. A. Lapchak, P. Maher, D. Schubert, and J. A. Zivin, “Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes,” *Neuroscience*, vol. 150, no. 3, pp. 585–591, 2007.

[82] Y. Fu, J. Luo, Z. Jia et al., “Baicalein protects against type 2 diabetes by promoting islet β-cell function in obese diabetic mice,” *International journal of endocrinology*, vol. 2014, Article ID 846742, 13 pages, 2014.

[83] R. Stavniuch, V. R. Drel, H. Shevalye et al., “Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation,” *Experimental Neurology*, vol. 230, no. 1, pp. 106–113, 2011.

[84] A. Ahad, M. Mujeeb, H. Ahsan, and W. A. Siddiqui, “Prophylactic effect of baicalein against renal dysfunction in type 2 diabetic rats,” *Biochimie*, vol. 106, pp. 101–110, 2014.

[85] H. M. El-Bassossy, N. A. Hassan, M. F. Mahmoud, and A. Fahmy, “Baicalein protects against hypertension associated with diabetes: effect on vascular reactivity and stiffness,” *Phytotherapy*, vol. 21, no. 12, pp. 1742–1745, 2014.

[86] K. H. Mian and S. Mohamed, “Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants,” *Journal of Agricultural and Food Chemistry*, vol. 49, no. 6, pp. 3106–3112, 2001.

[87] L. Ding, D. Lin, and X. Chen, “Luteolin enhances insulin sensitivity via activation of PPARY transcriptional activity in adipocytes,” *The Journal of Nutritional Biochemistry*, vol. 21, no. 10, pp. 941–947, 2010.

[88] Y. Liu, X. Fu, N. Lan et al., “Luteolin protects against high fat diet-induced cognitive deficits in obesity mice,” *Behavioural Brain Research*, vol. 267, pp. 178–188, 2014.

[89] G. G. Wang, X. H. Lu, W. Li, X. Zhao, and C. Zhang, “Protective effects of luteolin on diabetic nephropathy in STZ-induced diabetic rats,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2011, Article ID 323171, 7 pages, 2011.

[90] Z. Deqiu, L. Kang, Y. Jiali, L. Baolin, and L. Gaolin, “Luteolin inhibits inflammatory response and improves insulin sensitivity in the endothelium,” *Biochimie*, vol. 93, no. 3, pp. 506–512, 2011.

[91] Y. Ding, X. Shi, X. Shuai et al., “Luteolin prevents uric acid-induced pancreatic β-cell dysfunction,” *Journal of biomedical research*, vol. 28, no. 4, pp. 292–298, 2014.

[92] K. F. S. Ricardo, T. T. D. Oliveira, T. J. Nagem, A. D. S. Pinto, M. G. A. Oliveira, and J. F. Soares, “Effect of flavonoids morin; quercetin and nicotinic acid on lipid metabolism of rats experimentally fed with triton,” *Brazilian Archives of Biology and Technology*, vol. 44, no. 3, pp. 263–267, 2001.

[93] V. Sreedharan, K. K. Venkatachalam, and N. Namavasyam, “Effect of morin on tissue lipid peroxidation and antioxidant status in 1, 2-dimethylhydrazine induced experimental colon carcinogenesis,” *Investigational New Drugs*, vol. 27, no. 1, pp. 21–30, 2009.

[94] V. Sendrayaperumal, S. Iyyam Pillai, and S. Subramanian, “Design, synthesis and characterization of zinc-morin, a metal flavon complex and evaluation of its antidiabetic potential in HFD-STZ induced type 2 diabetes in rats,” *Chemico-Biological Interactions*, vol. 219, pp. 9–17, 2014.

[95] M. M. Rahman, F. Islam, A. Parvez et al., “*Citrus limon* (lemon) seed extract shows neuro-modulatory activity in an in vivo thiopental-sodium sleep model by reducing the sleep onset and enhancing the sleep duration,” *Journal of Integrative Neuroscience*, vol. 21, no. 1, p. 42, 2022.

[96] X. Wang, D.-M. Zhang, T.-T. Gu et al., “Morin reduces hepatic inflammation-associated lipid accumulation in high fructose-fed rats via inhibiting sphingosine kinase 1/sphin-gosine 1-phosphate signaling pathway,” *Biochemical Pharmacology*, vol. 86, no. 12, pp. 1791–1804, 2013.

[97] P. Paoli, F. Cirri, A. Caselli et al., “The insulin-mimetic effect of Morin: a promising molecule in diabetes treatment,” *Biochimica et Biophysica Acta*, vol. 1830, no. 4, pp. 3102–3111, 2013.

[98] M. T. Kabir, M. S. Uddin, P. Jeandet et al., “Anti-Alzheimer’s molecules derived from marine life: understanding molecular mechanisms and therapeutic potential,” *Marine Drugs*, vol. 19, no. 5, p. 251, 2021.

[99] J. Cordero-Herrera, M. A. Martin, L. Goya, and S. Ramos, “Cocoa flavonoids attenuate high glucose-induced insulin signalling blockade and modulate glucose uptake and production in human HepG2 cells,” *Food and Chemical Toxicology*, vol. 64, pp. 10–19, 2014.

[100] J. Yan, Z. Feng, J. Liu et al., “Enhanced autophagy plays a cardinal role in mitochondrial dysfunction in type 2 diabetic Goto-Kakizaki (GK) rats: ameliorating effects of (−)-epi-gallocatechin-3-gallate,” *The Journal of Nutritional Biochemistry*, vol. 23, no. 7, pp. 716–724, 2012.

[101] S. P. Yoon, Y. H. Maeng, R. Hong et al., “Protective effects of epigallocatechin gallate (EGCG) on streptozotocin-induced diabetic nephropathy in mice,” *Acta Histochemica*, vol. 116, no. 8, pp. 1210–1215, 2014.
Evidence-Based Complementary and Alternative Medicine

[103] S. B. Nicholas, J. Liu, J. Kim et al., “Critical role for osteopontin in diabetic nephropathy,” Kidney International, vol. 77, no. 7, pp. 588–600, 2010.

[104] N. Yamabe, T. Yokozawa, T. Oya, and M. Kim, “Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 1, pp. 226–236, 2006.

[105] A. Junaid and F. M. Amara, “Osteopontin: correlation with interstitial fibrosis in human diabetic kidney and PI3-kinase-mediated enhancement of expression by glucose in human proximal tubular epithelial cells,” Histopathology, vol. 44, no. 2, pp. 136–146, 2004.

[106] L. Bai, X. Li, L. He et al., “Antidiabetic potential of flavonoids from traditional Chinese medicine: a review,” American Journal of Chinese Medicine, vol. 47, no. 5, pp. 933–957, 2019.

[107] X. Wang, C. Feng, Y. Qiao, and X. Zhao, “Sigma 1 receptor mediated HMGB1 expression in spinal cord is involved in the development of diabetic neuropathic pain,” Neuroscience Letters, vol. 668, pp. 164–168, 2018.

[108] W. Wang, Y. Zhang, W. Jin, Y. Xing, and A. Yang, “Catechin weakens diabetic retinopathy by inhibiting the expression of nrf-b signaling pathway-mediated inflammatory factors,” Annals of Clinical and Laboratory Science, vol. 48, 2018.

[109] O. M. Ahmed, M. A. Hassan, S. M. Abdel-Twab, and M. N. Abdel Azeem, “Navel orange peel hydroethanolic extract, naringin and naringenin have anti-diabetic potentials in type 2 diabetic rats,” Biomedicine & Pharmacotherapy, vol. 94, pp. 197–205, 2017.

[110] G. Chen, G. Wei, J. Xu, X. Ma, and Q. Wang, “Naringin ameliorates the high glucose-induced rat mesangial cell inflammatory reaction by modulating the NLRP3 Inflammasome,” BMC Complementary and Alternative Medicine, vol. 18, no. 1, 2018.

[111] Z. Qi, Y. Xu, Z. Liang et al., “Naringin ameliorates cognitive deficits via oxidative stress, proinflammatory factors and the PPARγ signaling pathway in a type 2 diabetic rat model,” Molecular Medicine Reports, vol. 12, no. 5, pp. 7093–7101, 2015.

[112] A. M. Mahmoud, “Hematological alterations in diabetic rats: role of adipocytokines and effect of citrus flavonoids,” EXCLI Journal, vol. 12, 2013.

[113] P. Neerati, R. Devde, and A. K. Gangi, “Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus,” Phytotherapy Research, vol. 28, no. 12, pp. 1976–1980, 2014.

[114] M. R. Maradana, R. Thomas, and B. J. O’Sullivan, “Targeted delivery of curcumin for treating type 2 diabetes,” Molecular Nutrition & Food Research, vol. 57, no. 9, pp. 1550–1556, 2013.

[115] S. Chuengsamarn, S. Rattanamongkolgul, R. Luechapudiporn, C. Phisalaphong, and S. Jirawatnotai, “Curcumin extract for prevention of type 2 diabetes,” Diabetes Care, vol. 35, no. 11, pp. 2121–2127, 2012.

[116] B. Stefanska, “Curcumin ameliorates hepatic fibrosis in type 2 diabetes mellitus - insights into its mechanisms of action,” British Journal of Pharmacology, vol. 166, no. 8, pp. 2209–2211, 2012.

[117] P. P. Nahar, A. L. Slitt, and N. P. Seeram, “Anti-inflammatory effects of novel standardized solid lipid curcumin formulations,” Journal of Medicinal Food, vol. 18, no. 7, pp. 786–792, 2015.

[118] S. Sivabalan and C. V. Anuradha, “A comparative study on the antioxidant and glucose-lowering effects of curcumin and bisdemethoxycurcumin analog through in vitro assays,” International Journal of Pharmacology, vol. 6, no. 5, pp. 664–669, 2010.

[119] F. Vahid, H. Zand, E. Nosrat-Mirshekarloo, R. Najafi, and A. Hekmatoost, “The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review,” Gene, vol. 562, no. 1, pp. 8–15, 2015.

[120] X. Yuan, H. Li, H. Bai et al., “Synthesis of novel curcumin analogues for inhibition of 11β-hydroxysteroid dehydrogenase type 1 with anti-diabetic properties,” European Journal of Medicinal Chemistry, vol. 77, pp. 223–230, 2014.

[121] S. Nabavi, R. Thiagarajan, L. Rastrelli et al., “Curcumin: a natural product for diabetes and its complications,” Current Topics in Medicinal Chemistry, vol. 15, no. 23, pp. 2445–2455, 2015.

[122] Y. Huang, Y. Zhao, F. Liu, and S. Liu, “Nano traditional Chinese medicine: current progresses and future challenges,” Current Drug Targets, vol. 16, no. 13, pp. 1548–1562, 2015.

[123] A. Kumar, A. Ahuja, J. Ali, and S. Baboota, “Curcumin loaded nano globules for solubility enhancement: preparation, characterization and ex vivo release study,” Journal of Nanoscience and Nanotechnology, vol. 12, no. 11, pp. 8293–8302, 2012.

[124] A. Kumar, A. Ahuja, J. Ali, and S. Baboota, “Curcumin-loaded lipid nanocarrier for improving bioavailability, stability and cytotoxicity against malignant glioma cells,” Drug Delivery, vol. 23, no. 1, pp. 214–229, 2016.

[125] D. Ghosh, S. T. Choudhury, S. Ghosh et al., “Nanoencapsulated curcumin: oral cheopreventive formulation against diethylnitrosamine induced hepatocellular carcinoma in rat,” Chemico-Biological Interactions, vol. 195, no. 3, pp. 206–214, 2012.

[126] S. Prasad, A. K. Tyagi, and B. B. Aggarwal, “Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice,” Cancer Research and Treatment: Official Journal of Korean Cancer Association, vol. 46, no. 1, pp. 2–18, 2014.

[127] J. A. Molina-Bolivár and F. Galisteo-González, “Olive-oil nanocapsules stabilized by HSA: influence of processing variables on particle properties,” Journal of Nanoparticle Research, vol. 17, no. 10, pp. 1–13, 2015.

[128] Z. Zhang, R. Zhang, L. Zou et al., “Encapsulation of curcumin in polysaccharide-based hydrogel beads: impact of bead type on lipid digestion and curcumin bioaccessibility,” Food Hydrocolloids, vol. 58, pp. 160–170, 2016.

[129] G. H. Shin, J. Li, J. H. Cho, J. T. Kim, and H. J. Park, “Enhancement of curcumin solubility by phase change from crystalline to amorphous in cur-TPGS nanosuspension,” Journal of Food Science, vol. 81, no. 2, pp. N494–N501, 2016.

[130] U. Hani and H. G. Shivakumar, “Solubility enhancement and delivery systems of curcumin a herbal medicine: a review,” Current Drug Delivery, vol. 11, no. 6, pp. 792–804, 2014.

[131] P. Ramalingam, S. W. Yoo, and Y. T. Ko, “Nanodelivery of curcumin in advance nanocurcumin form in the treatment of diabetic rat model,” International Journal of Nanomedicine, vol. 8, no. 23, Article ID e78217, 2013.

[132] C. N. Grana, P. Suryanarayana, M. A. Patil et al., “Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model,” PLoS One, vol. 8, no. 10, Article ID e78217, 2013.

[133] P. Tagde, P. Tagde, F. Islam et al., “The multifaceted role of curcumin in advanced nanocurcumin form in the treatment and management of chronic disorders,” Molecules, vol. 26, no. 23, 2021.
[134] R. P. Joshi, G. Negi, A. Kumar et al., “SNEDDS curcumin formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: an insight into its mechanism for neuroprotection,” *Nanomedicine: Nanotechnology, Biology and Medicine*, vol. 9, no. 6, pp. 776–785, 2013.

[135] R. Vecchione, V. Quagliariello, D. Calabria et al., “Curcumin bioavailability from oil in water nano-emulsions: in vitro and in vivo study on the dimensional, compositional and intertactional dependence,” *Journal of Controlled Release*, vol. 233, pp. 88–100, 2016.

[137] Y.-M. Tsai, W.-C. Jan, C.-F. Chien, W.-C. Lee, L.-C. Lin, and T.-H. Tsai, “Optimised nano-formulation on the bioavailability of hydrophobic polyphenol, curcumin, in freely-moving rats,” *Food Chemistry*, vol. 127, no. 3, pp. 918–925, 2011.

[138] J. Wang, W. Ma, and P. Tu, “The mechanism of self-assembled mixed micelles in improving curcumin oral absorption: in vitro and in vivo,” *Colloids and Surfaces B: Biointerfaces*, vol. 133, pp. 108–119, 2015.

[139] V. M. Thadhan, “Resveratrol in management of diabetes and obesity: clinical applications, bioavailability, and nano-therapy,” *Resveratrol—Adding Life To Years, Not Adding Years To Life*, Intechopen, London, UK, 2019.

[140] A. Chimento, F. De Amicis, R. Sirianni et al., “Progress to improve oral bioavailability and beneficial effects of resveratrol,” *International Journal of Molecular Sciences*, vol. 20, no. 6, 2019.

[141] A. C. Santos, F. J. Veiga, J. A. D. Sequeira et al., “First-time oral administration of resveratrol-loaded layer-by-layer nanoparticles to rats - a pharmacokinetics study,” *Analyt*, vol. 144, no. 6, pp. 2062–2079, 2019.

[142] C. Yücel, G. Ş. Karatoparak, and Y. Aktaş, “Nanoliposomal resveratrol as a novel approach to treatment of diabetes mellitus,” *Journal of Nanoscience and Nanotechnology*, vol. 18, no. 6, pp. 3856–3864, 2018.

[143] C. Yücel, G. Şeker Karatoparak, and A. Atmar, “Novel resveratrol-loaded nanocochleates and effectiveness in the treatment of diabetes,” *Journal of Pharmaceutical Sciences*, vol. 43, pp. 35–44, 2018.

[144] R. Mohseni, Z. ArabSadeghabadi, N. Ziajamjidi, R. Abbassilpourkabir, and A. Rezaefarimani, “Oral administration of resveratrol-loaded solid lipid nanoparticle improves insulin resistance through targeting expression of SNARE proteins in adipose and muscle tissue in rats with type 2 diabetes,” *Nanoscale Research Letters*, vol. 14, no. 1, p. 227, 2019.

[145] F. Y. K. Siu, S. Ye, H. Lin, and S. Li, “Galactosylated PLGA nanoparticles for the oral delivery of resveratrol: enhanced bioavailability and in vitro anti-inflammatory activity,” *International Journal of Nanomedicine*, vol. 13, pp. 4133–4144, 2018.

[146] F. Islam, M. H. Nafady, M. Islam et al., “Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer’s disease from bench to bedside,” *Molecular Neurobiology*, vol. 59, p. 21, 2022.

[147] D. Chitkara, S. K. Nikalaje, A. Mittal, M. Chand, and N. Kumar, “Development of quercetin nanoformulation and in vivo evaluation using streptozotocin induced diabetic rat model,” *Drug Delivery and Translational Research*, vol. 2, no. 2, pp. 112–123, 2012.

[148] H. Li, X. Zhao, Y. Ma, G. Zhai, L. Li, and H. Lou, “Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles,” *Journal of Controlled Release*, vol. 133, no. 3, pp. 238–244, 2009.

[149] P. Mukhopadhyay, S. Maity, S. Mandal, A. S. Chakraborti, A. K. Prajapati, and P. P. Kundu, “Preparation, characterization and in vivo evaluation of pH sensitive, self- quercetin-succinylated chitosan-alginate core-shell-corona nanoparticle for diabetes treatment,” *Carbohydrate Polymers*, vol. 182, pp. 42–51, 2018.

[150] J. Singh, P. Mittal, G. Vasant Bonde, G. Ajmal, and B. Mishra, “Design, optimization, characterization and in-vivo evaluation of quercetin enveloped soluplus®/P407 micelles in diabetes treatment,” *Artificial Cells, Nanomedicine, and Biotechnology*, vol. 46, no. 3, pp. 5546–5555, 2018.

[151] S. Ebrahimpour, A. Esmaeili, and S. Beheshiti, “Effect of quercetin-conjugated superparamagnetic iron oxide nanoparticles on diabetes-induced learning and memory impairment in rats,” *International Journal of Nanomedicine*, vol. 13, pp. 6311–6324, 2018.

[152] S. M. Ding, Z. H. Zhang, J. Song, X. D. Cheng, J. Jiang, and X. B. Jia, “Enhanced bioavailability of apigenin via preparation of a carbon nanopowder solid dispersion,” *International Journal of Nanomedicine*, vol. 9, no. 1, pp. 2327–2333, 2014.

[153] S. Dewanjee, P. Chakraborty, B. Mukherjee, and V. De Feo, “Plant-based antidiabetic nanoformulations: the emerging paradigm for effective therapy,” *International Journal of Molecular Sciences*, vol. 21, no. 6, 2020.

[154] S.-Z. Liu, Y.-X. Deng, B. Chen, X.-J. Zhang, Q.-Z. Shi, and X.-M. Qiu, “Antihyperglycemic effect of the traditional Chinese scutellaria-cortis herb couple and its main components in streptozotocin-induced diabetic rats,” *Journal of Ethnopharmacology*, vol. 145, no. 2, pp. 490–498, 2013.

[155] B. Dinda, I. Sılşarma, M. Dinda, and P. Rudrapaul, “Oroxylum indicum (L.) Kurz, an important Asian traditional medicine: from traditional uses to scientific data for its commercial exploitation,” *Journal of Ethnopharmacology*, vol. 161, pp. 255–278, 2015.

[156] K. C. Leung, C. J. Seneviratne, X. Li et al., “Synergistic antibacterial effects of nanoparticles encapsulated with scutellaria baicalensis and pure chlorhexidine on oral bacterial biofilms,” *Nanomaterials*, vol. 6, no. 4, 2016.

[157] J. Zhang, H. Lv, K. Jiang, and Y. Gao, “Enhanced bioavailability after oral and pulmonary administration of baicalin nanocrystal,” *International Journal of Pharmacy*, vol. 420, no. 1, pp. 180–188, 2011.

[158] F. Shi, Z. Wei, Y. Zhao, and X. Xu, “Nanostructured lipid carriers loaded with baicalin: an efficient carrier for enhanced antidiabetic effects,” *Pharmacognosy Magazine*, vol. 12, no. 47, pp. 198–202, 2016.

[159] L. Zhao, Y. Wei, J. Fu, Y. Huang, B. He, and Y. Zhou, “Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation,” *International Journal of Nanomedicine*, vol. 8, pp. 3769–3779, 2013.

[160] Y. Wei, J. Guo, Z. Zheng et al., “Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes,” *International Journal of Nanomedicine*, vol. 9, no. 1, pp. 3623–3630, 2014.

[161] D. Majumdar, K.-H. Jung, H. Zhang et al., “Luteolin nanoparticle in chemoprevention: in vitro and in vivo
anticancer activity,” *Cancer Prevention Research*, vol. 7, no. 1, pp. 65–73, 2014.

[162] A. C. Puhl, M. Fagundes, K. Santos et al., “Preparation and characterization of polymeric nanoparticles loaded with the flavonoid luteolin, by using factorial design,” *International Journal of Drug Delivery*, vol. 3, no. 4, pp. 683–698, 2011.

[163] H. Dang, M. H. W. Meng, H. Zhao et al., “Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies,” *Journal of Nanoparticle Research*, vol. 16, no. 4, pp. 1–10, 2014.

[164] J. Naowaboot, S. Wannasiri, and P. Pannangpetch, “Morin attenuates hepatic insulin resistance in high-fat-diet-induced obese mice,” *Journal of Physiology & Biochemistry*, vol. 72, no. 2, pp. 269–280, 2016.

[165] P. Komirishetty, A. Areti, R. Sistla, and A. Kumar, “Morin mitigates chronic constriction injury (CCI)-Induced peripheral neuropathy by inhibiting oxidative stress induced PARP over-activation and neuroinflammation,” *Neurochemical Research*, vol. 41, no. 8, pp. 2029–2042, 2016.

[166] A. Caselli, P. Cirri, A. Santi, and P. Paoli, “Morin: a promising natural drug,” *Current Medicinal Chemistry*, vol. 23, no. 8, pp. 774–791, 2016.

[167] J. Zhang, X. Shuai, J. Li, N. Xi, T. Gong, and Z. Zhang, “Biodistribution, hypouricemic efficacy and therapeutic mechanism of morin phospholipid complex loaded self-nanoemulsifying drug delivery systems in an experimental hyperuricemic model in rats,” *Journal of Pharmacy and Pharmacology*, vol. 68, no. 1, pp. 14–25, 2016.

[168] T. Gong, J. Zhang, Q. Peng et al., “Preparation, characterization, and in vivo evaluation of a self-nanoemulsifying drug delivery system (SNEDDS) loaded with morin-phospholipid complex,” *International Journal of Nanomedicine*, vol. 6, p. 3405, 2011.

[169] J. Zhang, J. Li, Y. Ju, Y. Fu, T. Gong, and Z. Zhang, “Mechanism of enhanced oral absorption of morin by phospholipid complex based self-nanoemulsifying drug delivery system,” *Molecular Pharmaceutics*, vol. 12, no. 2, pp. 504–513, 2015.

[170] Y. A. Choi, Y. H. Yoon, K. Choi et al., “Enhanced oral bioavailability of morin administered in mixed micelle formulation with PluronicF127 and Tween80 in rats,” *Biological and Pharmaceutical Bulletin*, vol. 38, no. 2, pp. 208–217, 2015.

[171] Y. Ikeuchi-Takahashi, C. Ishihara, and H. Onishi, “Formulation and evaluation of morin-loaded solid lipid nanoparticles,” *Biological and Pharmaceutical Bulletin*, vol. 39, no. 9, pp. 1514–1522, 2016.

[172] J. Liu, J. Feng Lu, J. Kan, X. Yuan Wen, and C. Hai Jin, “Synthesis, characterization and in vitro anti-diabetic activity of catechin grafted insulin,” *International Journal of Biological Macromolecules*, vol. 64, pp. 76–83, 2014.

[173] E. Sistanipour, A. Meshkini, and H. Oveis, “Catechin-conjugated mesoporous hydroxyapatite nanoparticle: a novel nano-antioxidant with enhanced osteogenic property,” *Colloids and Surfaces B: Biointerfaces*, vol. 169, pp. 329–339, 2018.

[174] A. Granja, I. Frias, A. R. Neves, M. Pinheiro, and S. Reis, “Therapeutic potential of epigallocatechin gallate nano-delivery systems,” *BioMed Research International*, vol. 2017, Article ID 5813793, 15 pages, 2017.

[175] J. Liang, H. Yan, P. Puligundla, X. Gao, Y. Zhou, and X. Wan, “Applications of chitosan nanoparticles to enhance absorption and bioavailability of tea polyphenols: a review,” *Food Hydrocolloids*, vol. 69, pp. 286–292, 2017.

[176] A. Samanta and B. Bandyopadhyay, “Formulation of catechin hydrate nanocapsule and study of its bioavailability,” *Medicinal Chemistry*, vol. 6, no. 6, 2016.

[177] R. Yadav, D. Kumar, A. Kumari, and S. K. Yadav, “Encapsulation of catechin and epicatechin on BSA NPs improved their stability and antioxidant potential,” *EXCLI Journal*, vol. 13, 2014.

[178] B. Hu, Y. Ting, X. Zeng, and Q. Huang, “Bioactive peptides/chitosan nanoparticles enhance cellular antioxidant activity of (−)-epigallocatechin-3-gallate,” *Journal of Agricultural and Food Chemistry*, vol. 61, no. 4, pp. 875–881, 2013.

[179] W. Zhu and Z. Zhang, “Preparation and characterization of catechin-grafted chitosan with antioxidant and antidiabetic potential,” *International Journal of Biological Macromolecules*, vol. 70, pp. 150–155, 2014.

[180] J. F. Fangueiro, A. C. Calpena, B. Clares et al., “Biopharmaceutical evaluation of epigallocatechin gallate-loaded cationic lipid nanoparticles (EGCG-LNs); in vivo, in vitro and ex vivo studies,” *International Journal of Pharmaceutics*, vol. 502, no. 1–2, pp. 161–169, 2016.

[181] C.-Y. Chang, M.-C. Wang, T. Miyagawa et al., “Preparation of arginine−glycine−aspartic acid-modified biopolymeric nanoparticles containing epigallocatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization,” *International Journal of Nanomedicine*, vol. 12, pp. 279–294, 2016.

[182] S. S. Al-Rejaie, A. M. Aleisa, H. M. Abuohashish et al., “Naringenin neutralises oxidative stress and nerve growth factor discrepancy in experimental diabetic neuropathy,” *Neurological Research*, vol. 37, no. 10, pp. 924–933, 2015.

[183] R. Bhandari, A. Kuhad, J. K. Paliwal, and A. Kuhad, “Development of a new, sensitive, and robust analytical and bioanalytical RP-HPLC method for in-vitro and in-vivo quantification of naringenin in polymeric nanocarriers,” *Journal of Analytical Science and Technology*, vol. 10, no. 1, pp. 1–14, 2019.

[184] B. Zeng, K. Chen, P. Du et al., “Phenolic compounds fromClinopodium chinense (benth.) O. Kuntze and their inhibitory effects on α-glucosidase and vascular endothelial cells injury,” *Chemistry and Biodiversity*, vol. 13, no. 5, pp. 596–601, 2016.

[185] A. K. Keshari, G. Kumar, P. S. Kushwaha et al., “Isolated flavonoids from Ficus racemosa stem bark possess antidiabetic, hypolipidemic and protective effects in albino Wistar rats,” *Journal of Ethnopharmacology*, vol. 181, pp. 252–262, 2016.

[186] A. W. Khan, S. Kotta, S. H. Ansari, R. K. Sharma, and J. Ali, “Self-nanoemulsifying drug delivery system (SNEDDS) of the poorly water-soluble grapefruit flavonoid Naringenin: design, characterization, in vitro and in vivo evaluation,” *Drug Delivery*, vol. 22, no. 4, pp. 552–561, 2015.

[187] A. Shpigelman, Y. Shoham, G. Israeli-Lev, and Y. D. Livney, “β-Lactoglobulin-naringenin complexes: nano-vehicles for the delivery of a hydrophobic nutraceutical,” *Food Hydrocolloids*, vol. 40, pp. 214–224, 2014.
[188] F. L. Yen, T. H. Wu, L. T. Lin, T. M. Cham, and C. C. Lin, “Naringenin-loaded nanoparticles improve the physicochemical properties and the hepatoprotective effects of naringenin in orally-administered rats with CCl(4)-induced acute liver failure,” *Pharmaceutical Research*, vol. 26, no. 4, pp. 893–902, 2009.

[189] S. P. Kumar, K. Birundha, K. Kaveri, and K. T. R. Devi, “Antioxidant studies of chitosan nanoparticles containing naringenin and their cytotoxicity effects in lung cancer cells,” *International Journal of Biological Macromolecules*, vol. 78, pp. 87–95, 2015.